US Broker Ratings

The Cooper Companies, Inc. (COO)

⚠️ No article content returned.

..

Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: Exploring a 39% Potential Upside and Robust Revenue Growth

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) has made significant strides in the biotechnology sector, leveraging cutting-edge RNA interference technology to develop therapeutics for a range of diseases. With a market capitalization..

UnitedHealth Group (UNH) Stock Analysis: 18.61% Potential Upside Amid Robust Growth and Dividends

UnitedHealth Group Incorporated (NYSE: UNH), a titan in the healthcare sector with a market capitalization of $276.23 billion, offers a compelling opportunity for investors seeking stability and growth in a..

Natera, Inc. (NTRA) Stock Analysis: A $27.36 Billion Leader in Diagnostics with 33.96% Upside Potential

Natera, Inc. (NTRA), a prominent player in the healthcare sector, is garnering attention from investors with its cutting-edge diagnostics and research services. Headquartered in Austin, Texas, the company specializes in..

Mettler-Toledo International, Inc. (MTD) Stock Analysis: Uncovering a 13% Potential Upside in the Diagnostics & Research Sector

Mettler-Toledo International, Inc. (NYSE: MTD), a leader in precision instruments and services, presents an intriguing opportunity for investors in the healthcare sector, particularly within the diagnostics and research industry. With..

Sanofi (SNY) Stock Analysis: Exploring a 22% Potential Upside Amidst Strong Buy Ratings

Sanofi (NASDAQ: SNY), a prominent player in the healthcare sector, is capturing investor attention with a market capitalization of $113.88 billion. Headquartered in Paris, France, the company is a leader..

Humana Inc. (HUM) Stock Analysis: Navigating a 10.37% Potential Upside in Healthcare Plans

As one of the leading players in the healthcare plans sector, Humana Inc. (NYSE: HUM) presents a compelling opportunity for investors seeking exposure to the healthcare industry. With a market..

The Cigna Group (CI) Stock Analysis: Exploring a 24.9% Potential Upside

Investors eyeing opportunities in the healthcare sector may find The Cigna Group (NYSE: CI) a compelling candidate, given its robust market position and promising growth metrics. With a market capitalization..

GSK plc (GSK) Investor Outlook: Evaluating the Healthcare Giant’s Potential Amidst a 3.05% Dividend Yield

GSK plc (NYSE: GSK) stands as a formidable player in the healthcare sector, primarily engaged in the research, development, and manufacture of vaccines and specialty medicines. With a substantial market..

Danaher Corporation (DHR) Stock Analysis: Unveiling a 37.84% Potential Upside for Savvy Investors

Danaher Corporation (NYSE: DHR) stands as a formidable player in the healthcare sector, specifically within the diagnostics and research industry. With a market capitalization of $134.19 billion, this Washington D.C.-based..

Johnson & Johnson (JNJ) Stock Analysis: Navigating Growth with a 1.45% Potential Upside

Johnson & Johnson (NYSE: JNJ), a titan in the healthcare sector, continues to capture investor attention with its robust market presence and strategic positioning in the high-demand drug manufacturing industry...

Atrium Therapeutics, Inc. (RNA) Stock Analysis: Uncovering a Potential 86% Upside

Atrium Therapeutics, Inc. (NASDAQ: RNA) is making waves in the biotechnology sector as an emergent player in RNA-based therapies. With a focus on cardiomyopathies, the company is strategically positioned to..

Bausch + Lomb (BLCO) Stock Analysis: Eyeing an 11.96% Upside with Strategic Growth in Global Eye Health

Bausch + Lomb Corporation (NYSE: BLCO), a stalwart in the healthcare sector under the Medical Instruments & Supplies industry, has been crafting a significant presence in the global eye health..

Krystal Biotech, Inc. (KRYS) Stock Analysis: A 20% Upside Potential Beckons Investors

Krystal Biotech, Inc. (NASDAQ: KRYS), a prominent player in the biotechnology sector, continues to capture investor interest with its impressive market capitalization of $7.63 billion. As a commercial-stage biotechnology company,..

BridgeBio Pharma, Inc. (BBIO): Analyst Consensus Sees 37.58% Upside Potential in Biotech Innovator

BridgeBio Pharma, Inc. (NASDAQ: BBIO) has emerged as a focal point for investors keen on the biotechnology sector, thanks to its dynamic approach to addressing genetic diseases. Headquartered in Palo..

Prestige Consumer Healthcare (PBH) Stock Analysis: A 49.58% Upside Potential with Strong Buy Ratings

Prestige Consumer Healthcare Inc. (NYSE: PBH) stands out in the healthcare sector as a key player in the over-the-counter (OTC) health and personal care market. With a market capitalization of..

Lantheus Holdings, Inc. (LNTH) Stock Analysis: Exploring a 20% Potential Upside for Investors

Lantheus Holdings, Inc. (NASDAQ: LNTH) stands as a prominent player in the healthcare sector, specifically within the specialty and generic drug manufacturing industry. Based in Bedford, Massachusetts, the company has..

Alkermes plc (ALKS) Stock Analysis: Evaluating a 25% Potential Upside Amidst Market Challenges

Alkermes plc (NASDAQ: ALKS), the Dublin-based biopharmaceutical company, presents an intriguing investment opportunity within the healthcare sector, specifically in the specialty and generic drug manufacturing industry. With a market capitalization..

TG Therapeutics, Inc. (TGTX) Stock Analysis: Exploring a 32.5% Upside Potential in Biotech

TG Therapeutics, Inc. (NASDAQ: TGTX), a prominent player in the biotechnology sector, stands out as a compelling investment opportunity, particularly for those interested in healthcare innovations. With a market capitalization..

Halozyme Therapeutics, Inc. (HALO): Investor Outlook Reveals 31.63% Upside Potential in Biotech Sector

Halozyme Therapeutics, Inc. (NASDAQ: HALO), a prominent player in the biotechnology industry, is drawing attention from investors with its impressive valuation metrics and strategic partnerships. With a market capitalization of..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds